Sign in
Taking people in United StatesNo phase

Studies how semaglutide affects brown fat activity in people with obesity

Measures brown fat activity before and during semaglutide treatment in adults with obesity.

Key facts

Who runs it
University of California, Los Angeles
Where
Los Angeles, United StatesSee the site
Trial code
Registry title
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Status
Recruiting
People taking part
20 people, planned
Started
1 Feb 2023
Planned end
1 Feb 2026
Type of study
Observational
Treatments tested
  • Semaglutide Injectable Product (not provided by the study)
Record updated
11 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men and post-menopausal women who are about to start semaglutide for weight loss. The study does not provide the drug.

Age
Over 18 years
Sex
Men and post-menopausal women
Earlier treatment
People must be scheduled to start semaglutide for weight loss. Prior neck surgery or neck irradiation is not allowed.

Main reasons for not taking part

  • Prior neck surgery or neck irradiation
  • Use of beta blocker medicines or any other glucose lowering medicine
  • Diabetes or nerve disorders such as diabetic neuropathy
  • Abnormal thyroid function, cancer, or significant chronic, kidney, liver or hormone disease
  • Current smokers

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
  • >18 years of age and willing to participate
  • Male or post-menopausal females

Who cannot take part

  • History of prior neck surgery and /or neck irradiation; Use of beta blocker agents; Use of any other glucose lowering medication; History of neuropathic disorders (e.g. diabetic neuropathy); Diabetic patients; Individuals without normal thyroid function; Individuals with cancer; Any significant chronic disease or renal, hepatic or endocrine disease; Current smokers; Inability of patient to provide consent either for medical reasons or psychiatric reasons

Where in United States

  • UCLA HealthLos Angeles, United StatesContact: Julie Sorg, MSNTaking people

About the trial

What the trial wants to find out

Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role.

Read full original descriptionShow less

We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.

Treatments tested

  • Semaglutide Injectable Product (not provided by the study)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Plain-language title
Studies how semaglutide affects brown fat activity in people with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 May 2025